Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results